Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Richard

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Blood|May 12, 2019
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLSwati Garg, Armando Reyes-Palomares, Lixiazi He, et al.
Cell Reports|June 5, 2024
Immunotherapeutic targeting of surfaceome heterogeneity in AMLMarie-Eve Bordeleau, Éric Audemard, Arnaud Métois, et al.
Biomarker Research|April 14, 2025
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemiaArnaud Métois, Marie-Eve Bordeleau, Louis Theret, et al.
The Lancet. Haematology|June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trialElias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Blood|May 12, 2019
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLSwati Garg, Armando Reyes-Palomares, Lixiazi He, et al.
Cell Reports|June 5, 2024
Immunotherapeutic targeting of surfaceome heterogeneity in AMLMarie-Eve Bordeleau, Éric Audemard, Arnaud Métois, et al.
Biomarker Research|April 14, 2025
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemiaArnaud Métois, Marie-Eve Bordeleau, Louis Theret, et al.
The Lancet. Haematology|June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trialElias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Pageof 4